Table 1.
Effect of Br-MSCs, metformin and their combination on body weight (BW), heart weight (HW), and heart weight/body weight ratio (HW/BW) in adult male albino rats with cisplatin-induced cardiotoxicity.
| Groups | Body weight (BW) (gm) | Heart weight (HW)(gm) | Ratio (HW/BWx10–3) | |
|---|---|---|---|---|
| Initial | Final | |||
| Control | 222.7 ± 6.45 | 256.8 ± 10.04 | 0.65 ± 0.04 | 2.53 |
| Cisplatin treated | 221.8 ± 8.19 | 230.6 ± 7.96* | 0.51 ± 0.02* | 2.21* |
| Br- MSCs + Cis | 219.6 ± 6.93 | 246.3 ± 8.98*+ | 0.60 ± 0.03+ | 2.43+ |
| Metformin + Cis | 224.1 ± 9.43 | 242.7 ± 7.93*+ | 0.62 ± 0.05+ | 2.55+ |
| Br-MSCs + Metformin + Cis | 220.8 ± 9.35 | 252.5 ± 9.14+ | 0.64 ± 0.04+$ | 2.54+$ |
Cis cisplatin. Br-MSCs Breast Milk mesenchymal stem cells.
*P < 0.05 when compared with control, + P < 0.05 when compared with cisplatin.
$P < 0.05 when compared with Br-MSCs + cisplatin. Statistical analysis was done by using one way ANOVA test. Values were expressed as (mean ± SD).